Syros Pharmaceuticals Shares Plummet Premarket
Zacks.com on MSN22h
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary GoalShares of Syros Pharmaceuticals SYRS plunged 86.9% on Wednesday after a late-stage study of its only pipeline candidate, ...
Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...
Syros Pharmaceuticals’ stock has declined sharply for the second time in the past three months as a Phase III trial with ...
Syros Pharmaceuticals’ blood cancer prospect tamibarotene has failed another study, triggering a default on a loan and ...
With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on ...
Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from TD Cowen analyst Phil Nadeau yesterday. The company’s shares closed yesterday at $2.73. Nadeau covers ...
Syros Pharmaceuticals Inc.’s phase III failure with oral retinoic acid receptor alpha agonist tamibarotene in myelodysplastic syndrome (MDS) meant not only severe stock damage but also defaulting ...
NEW YORK – Syros Pharmaceuticals said on Tuesday that its retinoic acid receptor-alpha agonist tamibarotene, which it was testing in combination with azacitidine in patients newly diagnosed with ...
1d
Philadelphia, Pennsylvania-- (Newsfile Corp. - November 13, 2024) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or ...
TipRanks on MSN2d
Syros downgraded to Market Perform from Outperform at JMP SecuritiesJMP Securities analyst Jason Butler downgraded Syros Pharmaceuticals (SYRS) to Market Perform from Outperform without a price target The firm cites the “disappointing results” from the Phase 3 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback